Experimental KRAS G12D Degrader Plus Chemotherapy Shrinks Tumors in 6 of 7 Assessed Pancreatic Cancer Patients
An experimental drug designed to destroy the cancer-driving KRAS G12D protein, given with standard chemotherapy, shrank tumors in six of seven people with newly treated metastatic pancreatic cancer who had been scanned at least twice, according to early results presented Nov.